Cargando…

CYP2C19 loss‐of‐function alleles and use of omeprazole or esomeprazole increase the risk of cardiovascular outcomes in patients using clopidogrel

Our aim was to investigate in a real‐life prospective patient cohort how CYP2C19 loss‐of‐function (LOF) variants and CYP2C19 inhibitor omeprazole or esomeprazole influence the incidence of cardiovascular events in patients using clopidogrel. Data based simultaneously on these factors are conflicting...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramste, Markus, Ritvos, Markus, Häyrynen, Sergei, Kiiski, Johanna I., Niemi, Mikko, Sinisalo, Juha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582682/ https://www.ncbi.nlm.nih.gov/pubmed/37551775 http://dx.doi.org/10.1111/cts.13608

Ejemplares similares

Comparative efficacy of esomeprazole and omeprazole: Racemate to single enantiomer switch
por: Asghar, Waheed, et al.
Publicado: (2015)

Time-dependent association between omeprazole and esomeprazole and hospitalization due to hyponatremia
por: Issa, Issa, et al.
Publicado: (2022)

Oral esomeprazole vs injectable omeprazole for the prevention of hemorrhage after endoscopic submucosal dissection
por: Uchiyama, Takashi, et al.
Publicado: (2017)

Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8‐Mediated Metabolism of Montelukast in Humans
por: Itkonen, Matti K., et al.
Publicado: (2017)

Cost-Effectiveness and Cost–Utility Analysis of the Use of Clopidogrel and Pantoprazole in Comparison with Clopidogrel and Omeprazole for the Secondary Prevention of Myocardial Infarction in Iran
por: Amirsadri, Mohammadreza, et al.
Publicado: (2021)

Omeprazole- and Esomeprazole-associated Hypomagnesaemia: Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Tamura, Takao, et al.
Publicado: (2012)

Snapshot of the prescribing practice for the clopidogrel and esomeprazole coprescription and cost evaluation of the application guidelines
por: Vernaz, Nathalie, et al.
Publicado: (2016)

Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel
por: Itkonen, Matti K., et al.
Publicado: (2018)

A Case-Control Study of Esomeprazole Plus Rebamipide vs. Omeprazole Plus Rebamipide on Post-ESD Gastric Ulcers
por: Bunno, Maki, et al.
Publicado: (2013)

Comparison of ticagrelor and clopidogrel in the treatment of patients with coronary heart disease carrying CYP2C19 loss of function allele
por: Qian, Wenwen, et al.
Publicado: (2022)

Ensayo clínico para evaluar la eficacia del esomeprazol vs omeprazol en la enfermedad por reflujo gastroesofágico
por: Aguirre Cardoza, Rafael
Publicado: (2003)

Impact of CYP3A4*1G Allele on Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel
por: Danielak, Dorota, et al.
Publicado: (2016)

Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans
por: Elbe, Annika, et al.
Publicado: (2022)

Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2, and CYP2C9 variants
por: Lönnberg, K. Ivar, et al.
Publicado: (2023)

Effect of clopidogrel on the hydroxylation and sulfoxidation of omeprazole: A single dose study in healthy human volunteers
por: Ahmad, Lateef, et al.
Publicado: (2017)

Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution?
por: Kenngott, S, et al.
Publicado: (2010)

CYP2C19 loss-of-function alleles are not associated with clinical outcome of clopidogrel therapy in patients treated with newer-generation drug-eluting stents
por: Choi, Ik Jun, et al.
Publicado: (2016)

Interaction between Omeprazole and Gliclazide in Relation to CYP2C19 Phenotype
por: Dujic, Tanja, et al.
Publicado: (2021)

Effectiveness and safety of high dose clopidogrel plus aspirin in ischemic stroke patients with the single CYP2C19 loss-of-function allele: a randomized trial
por: Wu, Hongliang, et al.
Publicado: (2020)

Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype-dependent
por: Michaud, Veronique, et al.
Publicado: (2013)

Effects of omeprazole or pantoprazole on platelet function in non-ST-segment elevation acute coronary syndrome patients receiving clopidogrel
por: Gu, Ruo-Xi, et al.
Publicado: (2016)

Evaluation of CYP2C19 Gene Polymorphisms in Patients with Acid Peptic Disorders Treated with Esomeprazole
por: Díaz-Ordóñez, Lorena, et al.
Publicado: (2021)

Evaluation of CYP2C19-Mediated Pharmacokinetic Drug Interaction of Tegoprazan, Compared with Vonoprazan or Esomeprazole
por: Yang, Eunsol, et al.
Publicado: (2023)

Omeprazole Treatment Failure in Gastroesophageal Reflux Disease and Genetic Variation at the CYP2C Locus
por: Kee, Ping Siu, et al.
Publicado: (2022)

A synergic effect between CYP2C19*2, CYP2C19*3 loss-of-function and CYP2C19*17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients
por: Hassani Idrissi, Hind, et al.
Publicado: (2018)

Pharmaceutical intervention in the rational use of intravenous omeprazole
por: Araújo, Eduardo Silva, et al.
Publicado: (2019)

Safety assessment of omeprazole use: a review
por: Forgerini, Marcela, et al.
Publicado: (2018)

CYP2C19 loss-of-function alleles predicts clinical outcomes in East Asian patients with acute myocardial infarction undergoing percutaneous coronary intervention and stenting receiving clopidogrel
por: Chen, Yu-Wei, et al.
Publicado: (2022)

Effect of esomeprazole on the pharmacokinetics of carbamazepine
por: Medhi, Bikash, et al.
Publicado: (2011)

Implementation and management outcomes of pharmacogenetic CYP2C19 testing for clopidogrel therapy in clinical practice
por: Russmann, Stefan, et al.
Publicado: (2020)

CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome
por: Liu, Jian, et al.
Publicado: (2015)

Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients
por: Zhuo, Zhong-ling, et al.
Publicado: (2018)

Comparative Pharmacokinetics/Pharmacodynamics of Fixed-Dose Combination of Esomeprazole and Calcium Carbonate (AD-206) to the Conventional Esomeprazole
por: Bae, Sungyeun, et al.
Publicado: (2021)

Omeprazole use and risk of chronic kidney disease evolution
por: Guedes, João Victor Marques, et al.
Publicado: (2020)

Comment on “Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients”
por: Wang, Bin, et al.
Publicado: (2018)

Omeprazole-associated rhabdomyolysis
por: Tanaka, Kumiko, et al.
Publicado: (2014)

¿Omeprazol para todos?
por: Sánchez, Diego P., et al.
Publicado: (2014)

Phenotype of ASDs Associated With 4p16 Risk Locus and Novel Genome-Wide Associations of ASD Patients in the Finnish Population
por: Muroke, Valtteri, et al.
Publicado: (2023)

Pharmacokinetics of Esomeprazole in Critically Ill Patients
por: Xu, Yanyan, et al.
Publicado: (2022)

Hydroxylation index of omeprazole in relation to CYP2C19 polymorphism and sex in a healthy Iranian population
por: Payan, Maryam, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_enu8r94qt3gc495g4jtas2gcra